Filed Pursuant to Rule 424(b)(5)
Registration No. 333-259224
PROSPECTUS
SUPPLEMENT
(To prospectus dated September 8, 2021)
Up to $35,000,000
American Depositary Shares representing Ordinary Shares
We have entered into an equity distribution agreement, or the Distribution Agreement, with Oppenheimer & Co. Inc., or Oppenheimer,
dated April 22, 2022, relating to the sale of American Depositary Shares, or the ADSs, offered by this prospectus supplement. Each ADS represents ten fully paid ordinary shares, no par value per ordinary share. In accordance with the terms of the
Distribution Agreement, we may offer and sell ADSs having an aggregate offering price of up to $35,000,000 from time to time through Oppenheimer, pursuant to this prospectus supplement.
ADSs representing our ordinary shares are listed on the Nasdaq Capital Market under the symbol KZIA. Our ordinary shares are listed
on the Australian Securities Exchange under the symbol KZA. On April 18, 2022, the closing sale price of the ADSs on the Nasdaq Capital Market was $7.55 per ADS.
Sales of the ADSs, if any, under this prospectus supplement and the accompanying base prospectus may be made in sales deemed to be an at
the market offering as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, or the Securities Act, from time to time, including sales made directly on or through Nasdaq or any other existing trading market for
the ADSs. Oppenheimer is not required to sell any specific number or dollar amount of securities, but will use its commercially reasonable efforts consistent with its normal trading and sales practices, on mutually agreed terms between Oppenheimer
and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.
Oppenheimer will be entitled to
compensation at a commission rate of up to 3.0% of the gross proceeds from the sales of ADS sold under the Distribution Agreement. See Plan of Distribution beginning on page S-15 of this prospectus supplement for additional information
regarding the compensation to be paid to Oppenheimer.
In connection with the sale of the ADSs on our behalf, Oppenheimer will be deemed to
be an underwriter within the meaning of the Securities Act and the compensation of Oppenheimer will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to Oppenheimer
with respect to certain liabilities, including liabilities under the Securities Act or the Securities Exchange Act of 1934, as amended, or the Exchange Act.
We are a foreign private issuer, as defined under the federal securities laws, and, as such, we will be subject to reduced public
company reporting requirements for this prospectus supplement and future filings. See Prospectus SummaryImplications of Being a Foreign Private Issuer.
Investing in the ADSs involves risks. You should review carefully the risks and uncertainties described in the section titled Risk
Factors on page S-6 of this prospectus supplement, as well as in the documents incorporated or deemed to be incorporated by reference into this prospectus supplement and the accompanying prospectus,
concerning factors you should consider before buying the ADSs.
Neither the Securities and Exchange Commission nor any other regulatory body has
approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement and the accompanying prospectus. Any representation to the contrary is a criminal offense.
Oppenheimer & Co.
The date of this prospectus supplement is April 22, 2022.